| The future of cancer immunotherapy: microenvironment-targeting combinations YR Murciano-Goroff, AB Warner, JD Wolchok Cell Research 30 (6), 507-519, 2020 | 556 | 2020 |
| Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma MH Pollack, A Betof, H Dearden, K Rapazzo, I Valentine, AS Brohl, ... Annals of Oncology 29 (1), 250-255, 2018 | 335 | 2018 |
| Modulation of murine breast tumor vascularity, hypoxia, and chemotherapeutic response by exercise AS Betof, CD Lascola, D Weitzel, C Landon, PM Scarbrough, GR Devi, ... Journal of the National Cancer Institute 107 (5), djv040, 2015 | 286 | 2015 |
| Effects and potential mechanisms of exercise training on cancer progression: a translational perspective AS Betof, MW Dewhirst, LW Jones Brain, behavior, and immunity 30, S75-S87, 2013 | 268 | 2013 |
| Efficacy and mechanisms of aerobic exercise on cancer initiation, progression, and metastasis: a critical systematic review of in vivo preclinical data KA Ashcraft, RM Peace, AS Betof, MW Dewhirst, LW Jones Cancer research 76 (14), 4032-4050, 2016 | 223 | 2016 |
| Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer LW Jones, J Antonelli, EM Masko, G Broadwater, CD Lascola, D Fels, ... Journal of applied physiology 113 (2), 263-272, 2012 | 169 | 2012 |
| Impact of age on outcomes with immunotherapy for patients with melanoma AS Betof, RD Nipp, A Giobbie‐Hurder, RAN Johnpulle, K Rubin, ... The oncologist 22 (8), 963-971, 2017 | 167 | 2017 |
| Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade A Betof Warner, JS Palmer, AN Shoushtari, DA Goldman, KS Panageas, ... Journal of Clinical Oncology 38 (15), 1655-1663, 2020 | 157 | 2020 |
| Exercise as Adjunct Therapy in Cancer KA Ashcraft, AB Warner, LW Jones, MW Dewhirst Seminars in radiation oncology 29 (1), 16-24, 2019 | 153 | 2019 |
| Neoadjuvant relatlimab and nivolumab in resectable melanoma RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross, C Torres-Cabala, ... Nature 611 (7934), 155-160, 2022 | 147 | 2022 |
| Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L) 1 monotherapy: a multicentre, retrospective, cohort study IP da Silva, T Ahmed, ILM Reijers, AM Weppler, AB Warner, JR Patrinely, ... The Lancet Oncology 22 (6), 836-847, 2021 | 133 | 2021 |
| Effect of pazopanib on tumor microenvironment and liposome delivery TD Tailor, G Hanna, PS Yarmolenko, MR Dreher, AS Betof, AB Nixon, ... Molecular cancer therapeutics 9 (6), 1798-1808, 2010 | 118 | 2010 |
| Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors AC Guidon, LB Burton, BK Chwalisz, J Hillis, TH Schaller, AA Amato, ... Journal for immunotherapy of cancer 9 (7), 2021 | 113 | 2021 |
| Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma S Rosner, E Kwong, AN Shoushtari, CF Friedman, AS Betof, MS Brady, ... Cancer medicine 7 (3), 690-697, 2018 | 102 | 2018 |
| A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer Z Vujaskovic, DW Kim, E Jones, L Lan, L McCall, MW Dewhirst, ... International Journal of Hyperthermia 26 (5), 514-521, 2010 | 98 | 2010 |
| Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti–PD-1 monotherapy X Bai, J Hu, A Betof Warner, HT Quach, CG Cann, MZ Zhang, L Si, B Tang, ... Clinical Cancer Research 27 (21), 5993-6000, 2021 | 93 | 2021 |
| Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids A Tokunaga, D Sugiyama, Y Maeda, AB Warner, KS Panageas, S Ito, ... Journal of Experimental Medicine 216 (12), 2701-2713, 2019 | 92 | 2019 |
| T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants D Hirschhorn, S Budhu, L Kraehenbuehl, M Gigoux, D Schröder, A Chow, ... Cell 186 (7), 1432-1447. e17, 2023 | 64 | 2023 |
| Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis JT Yang, NA Wijetunga, E Pentsova, S Wolden, RJ Young, D Correa, ... Journal of Clinical Oncology 40 (33), 3858-3867, 2022 | 60 | 2022 |
| LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade R Shen, MA Postow, M Adamow, A Arora, M Hannum, C Maher, P Wong, ... Science Translational Medicine 13 (608), eabf5107, 2021 | 59 | 2021 |
Alexander N. ShoushtariAssistant Attending Physician, Memorial Sloan Kettering Cancer CenterVerified email at mskcc.org
